Candel Therapeutics Inc
CADL
Get informed when a big investor buys or sells
+ FollowMarket Cap$936.39M
Close$
$2.22
82.6% downside
Current Fair Value
82.6% downsideOvervalued by 82.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $936.39 Million |
|---|---|
| Enterprise Value | $784.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.72 |
| Beta | -0.5 |
| Outstanding Shares | 74,131,229 |
Return
| Return on Equity | -37.87% |
|---|---|
| Return on Assets | -22.95% |
| Return on Invested Capital | -30.56% |
Valuation & Multiples
| P/E Ratio | -9.06 |
|---|---|
| PEG | -1.27 |
| Price to Sales | - |
| Price to Book Ratio | 12.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.13 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3399▼ 4.00% |
|---|---|
| Total Calls | 309,800▼ 16.65% |
| Total Puts | 105,300▼ 25.42% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 68.65%▼ 0.99% |
|---|---|
| Total Invested | $524.57M▲ 146.37% |
| Investors Holding | 146▲ 28.00% |
ESG Score
No data
About Candel Therapeutics Inc
2,021 employees